在为期52周的临床研究中，Skye Bioscience Inc. 所开发的Nimacimab与司美格鲁肽（2.4毫克）联合疗法取得了令人瞩目的成果，受试者体重平均下降幅度达到22.3%。这一数据凸显了该联合方案在体重管理领域的巨大潜力。
Nimacimab作为一种创新治疗成分，与已广泛应用的司美格鲁肽协同作用，显示出优于单一疗法的减重效果。研究结果不仅证实了联合用药的安全性，更为其在肥胖治疗领域的应用前景提供了有力支持。
未来，Skye Bioscience Inc. 将继续推进相关临床研究，进一步探索该联合疗法的长期疗效与适用范围，为全球肥胖患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.